OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, is commenting today on a new research report by Transparency Market Research (TMR) that predicts the global thin film drug manufacturing market to be worth US $15.9 billion by the end of 2024.
According to the research report, the global market for thin film drug manufacturing will experience a compound annual growth rate (CAGR) of 9 percent from US $7.3 billion in 2015 to $15.9 billion by the end of 2024. The report also estimates the North American thin film manufacturing market, which accounted for a share of more than 66.6 percent in 2016, to emerge as a leading regional market. The report states that the growing demand for efficient drug delivery systems has augmented the uptake of thin film drugs due to their efficiency and effectiveness, with the convenience of transportation and storage encouraging patients to opt for these drugs.
“As the pre-eminent developer and manufacturer of the most advanced oral thin film (CureFilm™) on the market today, we are extremely encouraged by this new research report market and believe CURE is poised and well-positioned to play a leading role in this market moving forward,” said Rob Davidson, CEO of CURE Pharmaceutical. “As the report indicates, we see continued growth in this market as the healthcare industry continues to adopt groundbreaking drug delivery technologies such as OTF products, given their multitude of benefits including convenient administration, increased bioavailability and greater patient compliance.”
CURE Pharmaceutical’s patented, multilayer oral thin film, CureFilm™, is designed for oral administration. Without the need for water, it delivers medications to the tongue, cheek or sublingual regions of the mouth, allowing the medication to enter the blood stream enterically, buccally, or sublingually. CureFilm™ has been developed to improve upon the pharmacokinetic profile and the overall therapeutic index of an Active Pharmaceutical Ingredient (API). CureFilm™ technology enables delivery of higher doses of medications with better flavor masking.
CURE Pharmaceutical recently announced the publication of its “Crosslink” patent application by the Unites States Patent and Trademark Office (USPTO) that covers its proprietary CureFilm™ drug delivery technology to combine several active pharmaceutical ingredients (APIs) without negative interaction, showcasing the company’s continued dedication to further developments with oral thin film technology.
About CURE Pharmaceutical Headquartered in Oxnard, California, CURE Pharmaceutical (OTC:CURE) is a fully integrated specialty pharmaceutical/bioscience company that leverages disruptive proprietary drug delivery technologies for a broad range of molecules serving the biopharmaceutical, veterinarian, medical foods and pharmaceutical cannabis markets. CURE develops its patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today, from its industry leading full service cGMP manufacturing facility. The Company’s mission is to deliver proven drugs in a fast and efficient manner and to improve quality of life.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com .
About CURE Pharmaceuticals and Pharmaceutical Cannabis CURE Pharmaceutical is taking a leadership role in optimizing plant base cannabinoids, by vertically integrating drug discovery, proprietary extraction technology, genetic-specific cannabinoids research, and drug development. CURE’s strategy is to bring new cannabinoid molecules to the market through the FDA regulatory approval process while utilizing its proprietary delivery technologies to increase efficacy as well as widening the overall therapeutic index.
Forward-looking statements This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416
